← SynDRA
ALPELISIB
SynDRA canonical compound SYN0037409 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | PIK3CA |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
| Indication | breast cancer |
|---|
| Disease area | oncology |
|---|
All known targets
- PIK3CA
- PIK3CB
- PIK3CD
- PIK3CG
- GAK
- MTOR
- PRKACG
- Pik3cb
Mechanisms of action (all sources)
- PI3K inhibitor
- PIK3CA INHIBITOR
- PI3-kinase p110-alpha subunit inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- SYK
- PI4KB
- PGRMC1
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PAK4
- PAK2
- PAICS
- OPA1
- OLA1
- OGG1
- NUAK2
- NTHL1
- PHKG2
- PIK3C3
- NEK9
- PRKAG1
- PRKCI
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKACB
- PIM1
- PRKACA
- PRKAA1
- PLK4
- PKN2
- PKN1
- PKMYT1
- NQO2
- NEK3
- PRKD2
- MAPK15
- MAPKAPK5
- MAPKAPK2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- KSYK
- NSD2
- PIK3R1
- PK3CB
- PK3CD
- PK3CG
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- PIQRAY
- Piqray
- VIJOICE
- Vijoice
- piqray
- BYL-719
- NVP-BYL-719
- vijoice
- ALPELISIB (BYL719)
- BYL719
- NVP-BYL719
- BYL 719
- UNII-08W5N2C97Q
- Alpelisib (BYL719)
- CHEMBL2396661
- 08W5N2C97Q
- AK146107
- C19H22F3N5O2S
- Alpelisib [INN]
- 4jps
- 1LT
- Alpelisib [USAN]
- Piqray (TN)
- ALPELISIB [JAN]
- ALPELISIB [MI]
- Alpelisib [USAN:INN]
- ALPELISIB [WHO-DD]
- Alpelisib (JAN/USAN/INN)
- GTPL7955
- SCHEMBL1911869
- ALPELISIB [ORANGE BOOK]
- CHEBI:93752
- DTXSID70153355
- EX-A405
- BYL 719; BYL719
- BDBM50436459
- MFCD22417085
- NSC765974
Reported adverse events
- Abdominal pain
- Alanine aminotransferase
- Alopecia
- Angioedema
- Colitis
- Dry skin
- Dysgeusia
- Dyspepsia
- Fatigue
- Headache
- Hypersensitivity
- Lipase increased
Look up ALPELISIB in the interactive SynDRA portal →